A review of the processes and effects of droughts and summer floods in rivers and threats due to climate change on current adaptive strategies

Europe is expected to experience a greater frequency of floods and droughts as precipitation and evapotranspiration patterns are modified by climate change in future. Several large scale drought and flooding events have occurred in Europe since 2000. Studies of drought are rare but indicate important impacts on freshwater habitats, water quality, plants and animals, which may have wider consequences for ecosystem functioning. The main factors determining the impacts of droughts and floods are event duration and seasonality of the event. A diverse habitat distribution and the presence of refugia at the reach scale confer the most resilience against droughts and floods. Management measures will also be impacted particularly with regard to riparian zones, channel morphology, flow and floodplain connectivity. However there is a conflict between management actions that target the effects of drought, and those that target floods. This report reviews information on droughts and aseasonal floods (summer floods) published since 2000 with a principal focus on small lowland rivers. Using several recent (post 2000) reviews on these topics, we describe abiotic and biotic effects of droughts and floods, providing recent European examples where possible. We explain the current status of droughts and summer floods in Europe, and where the main sources of data can be found. We highlight the threats posed by these phenomena to some of the most common current adaptive management strategies in place in the EU. To this end we use measures already described within REFRESH under Deliverables 1.1 and 1.2, and we focused solely on adaptive measures relating to riparian zones, channel morphology, flow and floodplain connectivity

Investigating river wetted habitat sensitivity to flow change

This project aimed to improve the understanding of the response of river wetted habitat (represented by wetted perimeter WP) to change in flow (Q) in order to support ecological status and potential assessment in UK rivers impacted by abstraction/flow regulation, which is of high relevance to dam and hydropower scheme design. The analysis relied on a pool of >1,000 UK sites with good quality hydraulic data. A method to assess objectively WP sensitivity to Q was developed, which models WP as a function of Q in a consistent manner, then identifies three different sensitivity zones and corresponding flow thresholds mathematically (ranging from high sensitivity occurring at lower flows, medium sensitivity, and low sensitivity at higher flows). The study then investigated if wetted habitat sensitivity patterns could be related to catchment/river reach types. For c. two thirds of sites, WP was found highly sensitive to flow change at Q95 (5th percentile) or below, suggesting generic environmental flow values can mask variations in hydraulic sensitivity; there was no site featuring low WP sensitivity below Q95. Regarding typology, statistically significant patterns between sensitivity thresholds/ slopes and river types based on key catchment descriptors (area, altitude, permeability) were found; WP tend to be more sensitive to Q at higher flows for sites associated with smaller, lower elevation, and/or lower permeability catchments; sites with larger, higher elevation, and/or lower permeability catchments may feature sharper differences between sensitivity zones

Pyrolysis of Agricultural and Forestry Residues into Bio-oil

The pyrolysis of various agricultural wastes (grape residues, dried distillers grains, forestry residue and sugarcane residues) was carried out in a pilot-scale bubbling fluidized bed pyrolyzer operating at temperatures ranging from 300oC to 600oC , for vapor residence times ranging from 2 to 20 seconds. Products yields and properties, as well as process heat requirements were determined. The main objective was the optimization of the production of liquid bio-oil without any use of fossil fuel. The composition of the product gases was measured, from which their heating value was calculated. The liquid bio-oil was recovered with cyclonic condensers and separated into an aqueous phase and an organic phase. The environmental parameters for the disposal of the distilled fraction (85oC to 115oC) of a typical aqueous phase were determined, while the heating value of the organic phase was measured. Furthermore, the thermal sustainability of the pyrolysis process for each biomass was estimated by considering the energy contribution of the product gases and of the liquid bio-oil in relation to the pyrolysis heat requirements. The optimum pyrolysis temperatures were identified in terms of maximizing the liquid yield, maximizing the energy from the product bio-oil, and maximizing the net energy from the product bio-oil after ensuring a self-sustainable process by utilizing all the product gases and some of the bio-oil as heat sources. Different drying agents have been applied to the organic phase bio-oil to increase its heating value and therefore improve the fuel properties. The heating value can, thus, be increased by 21.5%. The results show that some biomasses are more suitable for the production of char, whereas others tend to produce more bio-oil or gas

Psychiatric diagnoses and punishment for misconduct: the effects of PTSD in combat-deployed Marines

<p>Abstract</p> <p>Background</p> <p>Research on Vietnam veterans suggests an association between psychological problems, including posttraumatic stress disorder (PTSD), and misconduct; however, this has rarely been studied in veterans of Operation Iraqi Freedom or Operation Enduring Freedom. The objective of this study was to investigate whether psychological problems were associated with three types of misconduct outcomes (demotions, drug-related discharges, and punitive discharges.)</p> <p>Methods</p> <p>A population-based study was conducted on all U.S. Marines who entered the military between October 1, 2001, and September 30, 2006, and deployed outside of the United States before the end of the study period, September 30, 2007. Demographic, psychiatric, deployment, and personnel information was collected from military records. Cox proportional hazards regression analysis was conducted to investigate associations between the independent variables and the three types of misconduct in war-deployed (n = 77 998) and non-war-deployed (n = 13 944) Marines.</p> <p>Results</p> <p>Marines in both the war-deployed and non-war-deployed cohorts with a non-PTSD psychiatric diagnosis had an elevated risk for all three misconduct outcomes (hazard ratios ranged from 3.93 to 5.65). PTSD was a significant predictor of drug-related discharges in both the war-deployed and non-war-deployed cohorts. In the war-deployed cohort only, a specific diagnosis of PTSD was associated with an increased risk for both demotions (hazard ratio, 8.60; 95% confidence interval, 6.95 to 10.64) and punitive discharges (HR, 11.06; 95% CI, 8.06 to 15.16).</p> <p>Conclusions</p> <p>These results provide evidence of an association between PTSD and behavior problems in Marines deployed to war. Moreover, because misconduct can lead to disqualification for some Veterans Administration benefits, personnel with the most serious manifestations of PTSD may face additional barriers to care.</p

An intrinsically disordered proteins community for ELIXIR.

Intrinsically disordered proteins (IDPs) and intrinsically disordered regions (IDRs) are now recognised as major determinants in cellular regulation. This white paper presents a roadmap for future e-infrastructure developments in the field of IDP research within the ELIXIR framework. The goal of these developments is to drive the creation of high-quality tools and resources to support the identification, analysis and functional characterisation of IDPs. The roadmap is the result of a workshop titled "An intrinsically disordered protein user community proposal for ELIXIR" held at the University of Padua. The workshop, and further consultation with the members of the wider IDP community, identified the key priority areas for the roadmap including the development of standards for data annotation, storage and dissemination; integration of IDP data into the ELIXIR Core Data Resources; and the creation of benchmarking criteria for IDP-related software. Here, we discuss these areas of priority, how they can be implemented in cooperation with the ELIXIR platforms, and their connections to existing ELIXIR Communities and international consortia. The article provides a preliminary blueprint for an IDP Community in ELIXIR and is an appeal to identify and involve new stakeholders

The ABC130 barrel module prototyping programme for the ATLAS strip tracker

For the Phase-II Upgrade of the ATLAS Detector, its Inner Detector, consisting of silicon pixel, silicon strip and transition radiation sub-detectors, will be replaced with an all new 100 % silicon tracker, composed of a pixel tracker at inner radii and a strip tracker at outer radii. The future ATLAS strip tracker will include 11,000 silicon sensor modules in the central region (barrel) and 7,000 modules in the forward region (end-caps), which are foreseen to be constructed over a period of 3.5 years. The construction of each module consists of a series of assembly and quality control steps, which were engineered to be identical for all production sites. In order to develop the tooling and procedures for assembly and testing of these modules, two series of major prototyping programs were conducted: an early program using readout chips designed using a 250 nm fabrication process (ABCN-25) and a subsequent program using a follow-up chip set made using 130 nm processing (ABC130 and HCC130 chips). This second generation of readout chips was used for an extensive prototyping program that produced around 100 barrel-type modules and contributed significantly to the development of the final module layout. This paper gives an overview of the components used in ABC130 barrel modules, their assembly procedure and findings resulting from their tests.Comment: 82 pages, 66 figure

Increased Skeletal Muscle 11βHSD1 mRNA Is Associated with Lower Muscle Strength in Ageing

Background: Sarcopenia, the loss of muscle mass and function with age, is associated with increased morbidity and mortality. Current understanding of the underlying mechanisms is limited. Glucocorticoids (GC) in excess cause muscle weakness and atrophy. We hypothesized that GC may contribute to sarcopenia through elevated circulating levels or increased glucocorticoid receptor (GR) signaling by increased expression of either GR or the GC-amplifying enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11βHSD1) in muscle. Methods: There were 82 participants; group 1 comprised 33 older men (mean age 70.2years, SD 4.4) and 19 younger men (22.2years, 1.7) and group 2 comprised 16 older men (79.1years, 3.4) and 14 older women (80.1years, 3.7). We measured muscle strength, mid-thigh cross-sectional area, fasting morning plasma cortisol, quadriceps muscle GR and 11βHSD1 mRNA, and urinary glucocorticoid metabolites. Data were analysed using multiple linear regression adjusting for age, gender and body size. Results: Muscle strength and size were not associated with plasma cortisol, total urinary glucocorticoids or the ratio of urinary 5β-tetrahydrocortisol +5α-tetrahydrocortisol to tetrahydrocortisone (an index of systemic 11βHSD activity). Muscle strength was associated with 11βHSD1 mRNA levels (β -0.35, p = 0.04), but GR mRNA levels were not significantly associated with muscle strength or size. Conclusion: Although circulating levels of GC are not associated with muscle strength or size in either gender, increased cortisol generation within muscle by 11βHSD1 may contribute to loss of muscle strength with age, a key component of sarcopenia. Inhibition of 11βHSD1 may have therapeutic potential in sarcopenia

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570